anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to medicine, and specifically to pharmaceutical compositions for providing targeted delivery of medicinal preparations. Producing a therapeutic wipe includes preparing a polymer base containing an alginic acid salt, and introducing an active substance which is proposed to consist of a substance selected from the proposed group in a therapeutically effective amount. Mixing this mixture in a low-speed mixer, applying the resulting composition to a textile material containing cellulose fibers, and drying same, wherein it is recommended to use a textile material comprised of at least 50% cellulose fibers. The composition of the polymer with the active substance should be applied to the textile material through a mesh template with a cell spacing of between 200 and 450 micrometers, until a continuous polymer layer is formed on the front surface of the textile material without seeping through to the reverse side. The use, according to the proposed method, of a composition having a viscosity of 25.0-50.0 Pa·s, with ϒ =3 с -1 , provides for the necessary technological viscosity. In addition, it is proposed to use the textile material in sheets, and to apply the mixture of polymer base and active substance through the mesh template by means of a trowel-like device. It is preferable to use a mixture of polymer base and active substance having a viscosity of 25.0-50.0 Pa·s, with ϒ =3 с -1 . The method allows for broadening the assortment of medicinal agents and biologically active additives, and for providing for varied concentrations thereof, thus allowing same to be used in the treatment of various diseases, while allowing for rapidly transforming the technological process and the economic feasibility thereof.
This group will consist of 35 primiparous pregnant women. The training program, prepared in line with travelbe's human-human relations model, will continue for a total of 4 weeks, 2 days a week.
PURPOSE: To obtain a medicinal composition containing a specific 2-phenyl-3- aroylbenzothiophene as active ingredient, and usable for a new therapy of uterine fibrosis. CONSTITUTION: This medicinal composition, which is intended for inhibiting uterine fibrosis, uses a compound of formula I [R<1> and R<3> are each H, CH3 , CO-(1-6C alkyl) or CO-Ar (Ar is phenyl); R<2> is pyrrolidino or piperidino] or a pharmaceutically acceptable salt or solvate thereof. The compound of formula I is pref. a hydrochloride thereof (in particular, a compound of formula II or hydrochloride thereof). This composition is pref. used for preventive administration. The compound of formula I is obtained by protecting, alkylating, and then deprotecting a benzo[b]thiophene bearing both 6-hydroxyl and 2-(4- hydroxyphenyl) groups. The daily dose of the compound of formula I is pref. about 50-200 mg or so. Furthermore, the compound of formula I and a gonadotropin-releasing hormone antagonist may be administered either simultaneously or consecutively.
DNA methylation and chromatin accessibility play important roles in gene expression, but their function in subgenome expression dominance remains largely unknown. We conducted comprehensive analyses of the transcriptome, DNA methylation, and chromatin accessibility in liver and muscle tissues of allotetraploid common carp, aiming to reveal the function of epigenetic modifications in subgenome expression dominance. A noteworthy overlap in differential expressed genes (DEGs) as well as their functions was observed across the two subgenomes. In the promoter and gene body, the DNA methylation level of the B subgenome was significantly different than that of the A subgenome. Nevertheless, differences in DNA methylation did not align with changes in homoeologous biased expression across liver and muscle tissues. Moreover, the B subgenome exhibited a higher prevalence of open chromatin regions and greater chromatin accessibility, in comparison to the A subgenome. The expression levels of genes located proximally to open chromatin regions were significantly higher than others. Genes with higher chromatin accessibility in the B subgenome exhibited significantly elevated expression levels compared to the A subgenome. Contrastingly, genes without accessibility exhibited similar expression levels in both subgenomes. This study contributes to understanding the regulation of subgenome expression dominance in allotetraploid common carp.
The present invention discloses medicine for treating burns and scalds, which contains calcined gypsum, red powder, red lead, borneol and calomelas as raw materials which are ground into powder to be evenly mixed. Vaseline is added to the mixture to be stirred to form the medicine. The medicine for treating burns and scalds of the present invention has the peculiar effects of obvious effect on pain alleviation, short treatment course, obvious effect, heat clearance, sterilization, inflammation elimination, pain alleviation, rotted tissue removal, muscle regeneration and no damage to regenerated cell tissues. The medicine for treating burns and scalds has the advantages of no scar after cure and no requirement of skin graft. During treatment, absorbent cotton gauze is used for packing besides external applied medicine paste, and an injury surface is prevented from contacting the outside to be infected. Particular equipment, such as a sterile room, a germicidal lamp, etc., is not required to be used. The present invention has no toxic or side effect.
The present invention relates to 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]-3-oxo-2,4-dioxobicyclo[3.2.1]octanes and derivatives thereof. In particular, hydroxyl, nitro, amino, amido, azido, oxime, thiol, ether and thiol ether derivatives of said carboxy group are contemplated. In particular, 7-[6-carboxy-2-hexenyl]-6-[3-hydroxy-1-octenyl] of 3-oxo-2,4-dioxobicyclo-[3.2.1 ]octane and derivatives thereof are disclosed. These compounds are useful as ocular hypotensives and as (a) thromboxane mimetics for the prevention of hemorrhaging as follows:, during surgery; tooth extraction; hemorrhaging associated with gastro-intestinal diseases and conditions such as hemorrhoids, inflammatory bowel diseases and gastric and peptic ulcers; as a result of stroke; as a complication in retinal diseases resulting in impaired vision and associated with-menstruation, childbirth and uterine dysfunction and (b) selective vasoconstrictors for treating systemic hypotension, e.g. in restoring normal blood pressure in hemorrhagic, anaphylactic, or septic shock victims; to provide local anti-inflammatory effects in the eye, skin and nose; to limit plasma exudation in burns, etc. and optimizing blood born delivery of drugs and diagnostics in encapsulating vehicles.
The pathogenesis of schizophrenia begins in early neurodevelopment and leads to excitatory-inhibitory imbalance. It is therefore essential that preclinical models used to understand disease, select drug targets and evaluate novel therapeutics encompass similar neurochemical deficits. One approach to improved preclinical modelling incorporates dual-hit neurodevelopmental insults, like neonatal administration of phencyclidine (PCP, to disrupt development of glutamatergic circuitry) then post-weaning isolation (Iso, to mimic adolescent social stress). We recently showed that male Lister-hooded rats exposed to PCP-Iso exhibit reduced hippocampal expression of the GABA interneuron marker calbindin. The current study expanded on this by investigating changes to additional populations of GABAergic interneurons in frontal cortical and hippocampal tissue from the same animals (by immunohistochemistry) as well as levels of GABA itself (via ELISA). Because inflammatory changes are also implicated in schizophrenia, we performed additional immunohistochemical evaluations of Iba-1 positive microglia as well as ELISA analysis of IL-6 in the same brain regions. Single-hit isolation-reared and dual-hit PCP-Iso rats both showed reduced parvalbumin immunoreactivity in the prelimbic/infralimbic region of the frontal cortex. However, this was more widespread in PCP-Iso, extending to the medial/ventral and lateral/dorsolateral orbitofrontal cortices. Loss of GABAergic markers was accompanied by increased microglial activation in the medial/ventral orbitofrontal cortices of PCP-Iso, together with frontal cortical IL-6 elevations not seen following single-hit isolation rearing. These findings enhance the face validity of PCP-Iso, and we advocate the use of this preclinical model for future evaluation of novel therapeutics-especially those designed to normalise excitatory-inhibitory imbalance or reduce neuroinflammation.
The study is designed as a prospective, double-blinded, randomize controlled study. The patients who will undergo mastectomy surgery with or without axillary dissection will be included in the study. Anesthesia will be inducted with intravenous (iv) thiopental 5 mg/kg, fentanyl 2 mcg/kg and rocuronium bromide 0.6 mg/kg. Following intubation, patients will be allocated into two groups according to a randomization table created by a professional statistician. In the study group, patients will receive a single shot Rhomboid Intercostal Block (RIB) with 30 milliliters of %0.25 bupivacaine and in the control group no block procedure will be performed. All patients will receive a standard analgesia protocol which will include an intraoperative intravenous (iv) infusion of dexketoprofen 50 mg and iv tramadol 1 mg/kg 15 minutes prior to the end of the surgery. Postoperative pain intensity of the patients will be evaluated by Numerical Rating Scale (NRS) which is a scale ranges between 0 (no pain) and 10 (the worst pain that a person can stand). Pain scores of the patients will be recorded at the postoperative 15. and 30. min in the recovery room and if the NRS score is 4 or more, iv fentanyl 1 mcg/kg will be applied. At the surgical ward, pain scores will be evaluated at the postoperative 1st, 2nd, 6th, 12th and 24th hours and if the NRS score is 4 or more, iv tramadol 50 mg will be applied as rescue analgesia. Opioid consumptions of the patients will be recorded at the postoperative 24th hour. At the postoperative 3. and 6. months, a pain doctor will evaluate all patients by using Brief Pain Inventory Short Form (BPI-SF) and Douleur Neuropathique 4 (DN4) questionnaire.
Weight gain is an important health concern, and disparities in the prevalence of obesity between African American and White women increase throughout the reproductive period. This study is a randomized, controlled trial testing the feasibility and acceptability of a peer-coach-administered, Facebook-delivered intervention to prevent weight gain in overweight and obese African American women. Study visits lasting approximately 1 hour will occur at baseline, post-intervention, and 1-month follow-up, to assess effectiveness and acceptability. The core intervention will occur over a 4-week period. Educational content in both the weight-gain prevention program and women's health program will be delivered via Facebook, with new content posted each weekday related to that week's topics. The peer coaches may contact participants via private messaging, when needed, to provide support and encourage engagement. If successful, this intervention could be easily disseminated to populations in under-served and community settings.
The complete structure of human milk BAL cDNA is disclosed. The nucleotide sequences of the cDNA inserts of two clones overlap and together contain 2951 base pairs of BAL cDNA which codes for an open reading frame of 720 amino acid residues between initiation and termination codons. There is a putative signal sequence of 20 residues which is followed by a 61-amino-terminal sequence of BAL. The cDNA sequence also contains a 678-base 5'-untranslated sequence, a 96-base 3'-untranslated region, and a 14-base poly(A) tail. The deduced BAL protein structure contains in the carboxyl-terminal region fourteen repeating units of 11 amino acids each. The repeating units have the basic structure of Pro-Val-Pro-Pro-Thr-Gly-Asp-Ser-Gly-Ala-Pro-, with only minor substitutions. The cDNA is useful for expression of protein, study of structure, function and the effect of modification or deletion or addition of amino acids, including entire repeating units, and as probes for studies involving BAL or related lipases, including rat pancreatic lysophospholipase, cholinesterase, and acetylcholinesterase. <IMAGE>   <IMAGE>
BACKGROUND: Yeast biomass, encompassing fatty acids, terpenoids, vitamins, antioxidants, enzymes, and other bioactive compounds have been extensively utilized in food-related fields. The safety and potential bioactivities of Scheffersomyces segobiensis DSM 27193, an oleaginous yeast strain, are unclear.
RESULTS: Scheffersomyces segobiensis DSM 27193 accumulated large palmitoleic acid (POA) levels (43.4 g kg-1 biomass) according to the results of whole-cell components. We annotated the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and predicted the categories and host of the pathogen-host interactions (PHI) genes in S. segobiensis DSM 27193. However, S. segobiensis DSM 27193 did not exert toxic effects in mice. Administration of S. segobiensis DSM 27193 led to substantial weight reduction by diminishing food intake in an obesity mouse model. Additionally, it reversed hepatic steatosis and adipose tissue hypertrophy, and improved abnormalities in serum biochemical profiles such as triglyceride, total cholesterol, low-density lipoprotein cholesterol, lipopolysaccharide, tumor necrosis factor-α, interleukin-1β, and interleukin-6.
CONCLUSION: This study is the first to illustrate the safety and effects of S. segobiensis DSM 27193 against obesity and offers a scientific rationale for its application in functional food supplements. © 2023 Society of Chemical Industry.
Hemiplegia in the shoulder complex and upper limb is a common secondary impairment as a result of a cerebrovascular event. Although most stroke survivors regain independent ambulation, many fail to regain functional use of their impaired upper limb. Actually the pathogenesis of post-stroke shoulder pain seems to be multifactorial; differential diagnosis is often difficult. Changes in the shoulder complex makes the glenohumeral joint vulnerable to subluxation, which may cause pain. Traction of capsule and soft tissue related subluxation of the shoulder may take place in the early stages; limited range of motion due to spasticity may develop in the later stages of stroke. These biomechanical problems may be the possible reason for pain. Rotator cuff tears and rotator cuff and deltoid tendinopathies are also possible symptoms related to hemiplegic shoulder observed in magnetic resonance imaging findings. These problems in the shoulder disturb the kinetic chain system that connects the segments and works sequentially from proximal to distal to achieve the targeted movement. When a biomechanical impairment happens in the shoulder or any other segment of the body, a loss in the energy produced in the body and transferred to the upper extremity occurs. This loss adversely affects the quality of the movement .

Regaining functional use of the upper limb after a stroke is a challenging task for the patient, which has a significant impact on the individual's physical, psychological, and emotional well-being. Lack of functional ability in the upper extremities after stroke restricts use and causes asymmetric posture and contracture in daily life, thus exacerbating functional limitations of the upper limb. Also, low upper limb motor function is related to the risk of soft tissue injury during rehabilitation. A patient experienced a stroke may not feel any pain due to subluxation. However, different muscle groups may be vulnerable to overstretching, increased contraction, and premature fatigue. This can decrease the coordination of muscular activity and inhibit the functional use of the upper extremity. The posterior fibers of the deltoid, the supraspinatus, and the infraspinatus are the most important muscles that prevent the subluxation of the glenohumeral joint.
Participants will receive a modified health education program on healthy aging. It will match the number and length of sessions as the hearing intervention, including compliance/phone checks. Participants will be on a waitlist to obtain hearing aids without fee at the end of their 12-month participation.
Wide spectrum anthelmintic compositions suitable for administration to domestic animals comprise as active ingredients a metal arsenate and a 2-substituted benzimidazole of formula <FORM:1095908/A5-A6/1> and non-toxic addition salts thereof, where R is thiazolyl, thiadiazolyl, isothiazolyl, pyrryl furyl, thienyl or phenyl, R1 is H, a C1-5 alkyl or a C2-5 alkenyl and R2 and R3 are H, a C1-5 alkyl or C1-5 alkoxy, or trifluoromethyl.  Many benzimidazole compounds are specified; the the most preferred are 2-(4\sv-thiazolyl) benzimidazole and 2-phenyl benzimidazole.  The metal arsenate is selected from arsenates of Al, Ca, Co, Cu, Sn, Fe, Zn and Pb.  The weight ratio of benzimidazole to arsenate may be from 1:0.04 to 1:1.35 and the combined weight of benzimidazole and arsenate may comprise 30-95% by weight of the composition.  Optional ingredients, particularly when the composition is in the form of a drench, include suspending agents, preservatives and antifoaming compounds.  The compositions may take the form of a drench, tablet, bolus, water-dispensible powder, aqueous solution, animal feedstuff or feedstuff supplement, pelleted animal feed or salt lick or block.
The goal is to look for predictive factors of poor oral health and the impact of poor oral health on the complications of diabetes. The prevalence of periodontal disease among patients with diabetes is higher than in the general population. Periodontal disease is associated with dental loss and increased systemic inflammation which is associated with cardiovascular and bone disease. However, current evidence that treatment of POD will result in improvement of outcomes in patients with diabetes is mixed. Identifying patterns of disease and following biomarkers in patients with diabetes and periodontal disease will answer some of the questions and result in more appropriate recommendations and interventions with reduction in morbidity, mortality and healthcare cost.

This study will be conducted using a cross-sectional design. Investigators will survey 200 consecutive patients with diabetes during routine clinic visits using a questionnaire. Investigators will collect data on demographic information, socio-economic status, oral health status/care, diabetes history (duration, control and complications) and bone health. A subgroup of 24 participants with survey responses suggestive of periodontal disease will be selected to receive treatment for periodontal disease. We will measure their hemoglobin A1c and biomarkers before and after treatment and will compare their levels for changes with treatment. Investigators will analyze collected data using test of proportions, Student's t-test and multivariate regression analyses.
Patients receive acalabrutinib PO BID on days 1-28. Starting cycle 2 day 1, patients also receive venetoclax PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE OF REVIEW: This literature review critically examines existing studies on cervical spinal cord stimulation (cSCS) for the treatment of chronic pain. The objective is to evaluate the current evidence, identify knowledge gaps, and collate data to inform clinical decision-making and suggest future research avenues. The review covers indications, contraindications, surgical and anesthetic approaches, trials, efficacy, and complications of cSCS.
RECENT FINDINGS: Recent advancements highlight the evolving role of cSCS in chronic pain management. New neuromodulation techniques involve optimal placement of leads based on the pain's innervation level, maximizing therapeutic outcomes. Contemporary studies underscore the broadening benefits of cSCS, including enhanced functional abilities and sleep quality. However, alongside these innovations come challenges; emerging data bring attention to complications such as hardware issues and infections. Significantly, modern research emphasizes the crucial role of accurate patient selection, factoring in prior therapy responses and comprehensive evaluations. cSCS emerges as a promising tool for chronic pain management, with benefits beyond mere pain relief. As surgical techniques, patient selection criteria, and postoperative care refine, the potential of cSCS expands to benefit a broader patient demographic. However, further comprehensive research is necessary to enhance its application, validate its role earlier in treatment, and ultimately ameliorate the lives of those with chronic pain.
This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.
The invention provides a method for preparing donkey hide gelatin oligo-peptide and relates to a process for extracting pharmacodynamic substance from traditional Chinese medicine. The protein in the medicine normally can be absorbed and utilized by an organism only after being decomposed into the oligo-peptide or amino acid by the digestive juice enzyme. The collagen protein, which accounts for 80% of the content of the donkey hide gelatin, is difficult to be digested and absorbed, so that the due drug effect can not be produced. The method adopts the bionic principle and technology, i.e. extracting the pharmacodynamic substance of the oligo-peptide from the donkey hide gelatin by using the biological enzymolysis technology and the ultrafiltration technology. First, pepsin and trypsinase are added to the raw medicine of the donkey hide gelatin for hydrolyzation at a certain pH value and a certain temperature; then, ultrafiltration is conducted by using a 3kD or 5kD ultrafiltration column to obtain an ultrafiltrate, which is then separated and purified by using a macroporous resin column to further obtain a donkey hide gelatin oligo-peptide eluate; finally, the obtained donkey hide gelatin oligo-peptide eluate is decompressed, concentrated at a low temperature and dried to become the finished product of donkey hide gelatin oligo-peptide, which is verified by the pharmacodynamic test, has the efficacies of increasing the blood, enhancing the immunity of the organism, anti-aging, etc., and meanwhile provides the process and raw material for preparing other oral liquids and injections.